Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
In a patient with metastatic PIK3CA-mutant, HR-positive, HER2-low breast cancer who is intolerant to capivasertib, would you consider treatment with alpelisib plus fulvestrant or with Enhertu?
Related Questions
For patients with PI3K mutated metastatic breast cancer who progress on a PI3K inhibitor, will you use an alternative PI3K inhibitor subsequently?
In which breast cancer presentation would you consider earlier treatment with T-DXd, given the similar absolute PFS benefits seen with T-DXd in the DESTINY-Breast06 trial and DESTINY-Breast04 trials?
What is your experience and treatment efficacy of tucatinib if used after enhertu in metastatic breast cancer?
For patients with ER-negative HER2-ultralow breast cancer, how and when would you incorporate T-DXd?
Is there benefit of cold-cap use while patient is on sacituzumab-govitecan?
What are your top takeaways in Breast Cancer from ESMO 2024?
At what time points during a patient's treatment for metastatic ER+ breast cancer are you checking liquid NGS for endocrine pathway alterations?
Is there any data to use PIK3CA-directed agents in mutated metastatic triple-negative breast cancer?
How do you reconcile data from PATINA trial and DESTINY-Breast09 with respect to CDK4/6 inhibitor maintenance in metastatic HER 2+ breast cancer?
How do you treat front line de novo HER2 positive metastatic breast cancer with brain metastases?
